Primary immunodeficiency diseases and malignancy in Japan

Area of Science:

• Immunology
• Oncology
• Genetics

Background:

• Primary immunodeficiency diseases (PIDs) are a group of inherited disorders that impair the immune system's ability to fight infections.
• An increased risk of developing certain cancers, particularly lymphoproliferative disorders and carcinomas, has been observed in individuals with PIDs.
• The All-Japan Immunodeficiency Registry collects data on patients with PIDs to understand disease patterns and outcomes.

Purpose of the Study:

• To investigate the incidence of malignant diseases in patients with primary immunodeficiency diseases registered in Japan.
• To compare the cancer risk in specific PIDs, such as ataxia-telangiectasia, Chediak-Higashi syndrome, and Wiskott-Aldrich syndrome, with international data.
• To assess the burden of malignancy in childhood PID patients compared to the general population.

Main Methods:

• Analysis of data from the All-Japan Immunodeficiency Registry, including 683 patients with PIDs.
• Calculation of malignancy incidence rates for specific PIDs and comparison with normal Japanese childhood population data.
• Comparison of findings with international statistics from the Immunodeficiency Cancer Registry.

Main Results:

• A total of 3.2% (22 out of 683) of PID patients developed malignant diseases.
• Childhood patients with ataxia-telangiectasia showed a malignancy death incidence approximately 625 times higher than the normal Japanese childhood population.
• High incidences of specific cancers were observed: 37.5% lymphoproliferative disorders in Chediak-Higashi syndrome and 13.7% non-Hodgkin lymphoma/carcinomas in ataxia-telangiectasia.

Conclusions:

• Patients with primary immunodeficiency diseases have a significantly elevated risk of developing malignancies.
• Ataxia-telangiectasia presents a particularly high risk for malignancy, necessitating close monitoring and early detection strategies.
• These findings underscore the importance of cancer surveillance in individuals diagnosed with primary immunodeficiency diseases.